Filtered By:
Specialty: Endocrinology
Condition: Bleeding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats
In conclusion, the protein and gene expression changes in the vagina by Gelam honey had reduced the occurrence of vaginal atrophy in surgically-induced menopause models.
Source: Frontiers in Endocrinology - February 27, 2023 Category: Endocrinology Source Type: research

Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
ConclusionsIn these T2DM patients with ACS, a significantly lower risk of major adverse cardiovascular events including all-cause mortality was observed in the ticagrelor group compared with the clopidogrel group. However, T2DM patients who were assigned to ticagrelor showed a significantly higher minor bleeding risk. Larger clinical trials should be able to confirm these hypotheses.
Source: Diabetes Therapy - December 21, 2022 Category: Endocrinology Source Type: research

Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: a meta-analysis of outcome trials
Direct oral anticoagulants (DOACs) are gradually replacing warfarin in the treatment of non-valvular atrial fibrillation because outcome comparison trials were constantly associated with a reduction of 1) stroke or systemic embolism events, and 2) major bleeding events [1 –4]. Whether the beneficial effect of DOACs vs warfarin on fatal and non-fatal outcomes is consistent to patients with or without diabetes mellitus (DM) has been previously approached by meta-analyses of the available outcome trials [5–7], in which no differential outcome effect was noticed.
Source: Diabetes Research and Clinical Practice - November 15, 2021 Category: Endocrinology Authors: Sotirios Drogkaris, Costas Thomopoulos, Theodoros Kalos, Eleni Manta, Costas Tsioufis Source Type: research

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis
ConclusionDiscontinuing ASA after short-term use for the treatment of patients with T2DM following PCI was not associated with any increased cardiovascular outcomes. Also, discontinuing ASA after short-term use and continuing the use of a P2Y12 inhibitor were somewhat safer in these patients with T2DM. Further research should follow.
Source: Diabetes Therapy - September 23, 2020 Category: Endocrinology Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation Patients with Concomitant Hyperthyroidism.
CONCLUSION: Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study. PMID: 32009154 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - February 2, 2020 Category: Endocrinology Authors: Chan YH, Wu LS, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF, Lip GYH Tags: J Clin Endocrinol Metab Source Type: research

The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants
AbstractDirect oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current evidence regarding DOAC use in diabetic patients included in the majority of recently conducted studies. Overall, in trials involving patients with atrial fibrillation, data seem to confirm at least a similar efficacy and ...
Source: Acta Diabetologica - September 23, 2019 Category: Endocrinology Source Type: research

Ticagrelor Versus Prasugrel for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
ConclusionTicagrelor and prasugrel were not associated with significantly different adverse clinical outcomes and bleeding events in these patients with T2DM. Therefore, both antiplatelet agents might safely be used in patients with T2DM following coronary intervention. However, this head-to-head comparison still remains a major challenge which should be resolved in larger clinical trials.
Source: Diabetes Therapy - November 19, 2018 Category: Endocrinology Source Type: research

An Urban 911 System's Experience with Left Ventricular Assist Device Patients.
CONCLUSIONS: EMS interactions with LVAD patients are infrequent but have high rates of admission and incidence of life-threatening diagnoses. The most common prehospital presenting symptoms were weakness and chest pain, and most prehospital interactions did not require LVAD-specific interventions. In addition to acquiring technical knowledge regarding LVADs, EMS providers should be aware of non-device-related complications including intracranial and GI bleeding and take this into account during their assessment. PMID: 30285520 [PubMed - as supplied by publisher]
Source: Prehospital Emergency Care - October 6, 2018 Category: Endocrinology Tags: Prehosp Emerg Care Source Type: research

Use of non ‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
ConclusionsThe efficacy and safety of non‐vitamin K oral anticoagulants compared with warfarin generally extend to participants with diabetes mellitus, although dedicated randomized trials or real‐world data are lacking.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - February 13, 2018 Category: Endocrinology Authors: O. Itzhaki, B. Zadok, A. Eisen Tags: Review Source Type: research

Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus
ConclusionsThis study indicates a significantly more intense DE‐induced anticoagulation in diabetic rats that does not seem to be solely related to altered kidney function, and demonstrates that plasma cholesterol can significantly affect DE‐anticoagulation in this setting. These results could explain the similar benefits of DE on stroke prevention in patients with and without DM, despite the significantly higher intrinsic thrombotic risk of the former, as well as the lack of benefit of reducing major bleeding in diabetics.
Source: Journal of Diabetes - July 1, 2017 Category: Endocrinology Authors: Alina Scridon, Marcel Perian, Alina M ărginean, Adina Huțanu, Doina Gherțescu, Adriana Vântu, Paul Ciprian Fișcă, Philippe Chevalier, Răzvan Constantin Șerban, Dan Dobreanu Tags: Original Article Source Type: research

Pathophysiological consequences of receptor mistraffic: Tales from the platelet P2Y12 receptor
Publication date: Available online 14 February 2017 Source:Molecular and Cellular Endocrinology Author(s): Margaret R. Cunningham, Riyaad Aungraheeta, Stuart J. Mundell Genetic variations in G protein-coupled receptor (GPCR) genes can disrupt receptor function in a wide variety of human genetic diseases, including platelet bleeding disorders. Platelets are critical for haemostasis with inappropriate platelet activation leading to the development of arterial thrombosis, which can result in heart attack and stroke whilst decreased platelet activity is associated with an increased risk of bleeding. GPCRs expressed on the sur...
Source: Molecular and Cellular Endocrinology - February 14, 2017 Category: Endocrinology Source Type: research

Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study ‐level meta‐analysis of phase III randomized trials
In this study‐level meta‐analysis, we included 4 randomized phase III trials comparing NOACs and warfarin in patients with nonvalvular AF; a total of 18 134 patients with DM and 40 454 without DM were overall considered. Incidence of the following outcome measures was evaluated during the follow‐up: stroke or systemic embolism, ischemic stroke, major bleeding, intracranial bleeding, and vascular death. Use of NOACs compared with warfarin reduced stroke/systemic embolism in diabetic (Risk Ratios [RR] 0.80, 95% CI 0.68‐0.93; P = .004) and nondiabetic patients (RR 0.83, 0.73‐0.93; P = .001) (P for interaction ...
Source: Diabetes/Metabolism Research and Reviews - January 26, 2017 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research

Safety and efficacy of non ‐vitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study‐level meta‐analysis of phase III randomized trials
ConclusionsResults of this meta‐analysis support the safety and efficacy of NOACs compared with warfarin in diabetic patients with non‐valvular AF.
Source: Diabetes/Metabolism Research and Reviews - October 31, 2016 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research

Aspirin for primary prevention of cardiovascular and all ‐cause mortality events in diabetes: updated meta‐analysis of randomized controlled trials
ConclusionsThe emerging data do not clearly support guidelines that encourage the use of aspirin for the primary prevention of cardiovascular disease in adults with diabetes who are at increased cardiovascular disease risk.
Source: Diabetic Medicine - May 21, 2016 Category: Endocrinology Authors: S. K. Kunutsor, S. Seidu, K. Khunti Tags: Systematic Review or Meta ‐analysis Source Type: research